Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Ramucirumab> ?p ?o. }
Showing items 1 to 57 of
57
with 100 items per page.
- Ramucirumab abstract "Ramucirumab (IMC-1121B, trade name Cyramza) is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. It is directed against the vascular endothelial growth factor receptor 2 (VEGFR2). By binding to VEGFR2 it works as a receptor antagonist blocking the binding of vascular endothelial growth factor (VEGF) to VEGFR2. VEGFR2 is known to mediate the majority of the downstream effects of VEGF in angiogenesis.Ramucirumab is being tested in several phase III clinical trials for the treatment of metastatic gastric adenocarcinoma, non-small cell lung cancer, among other types of cancer. On September 26, 2013 the manufacturer Eli Lilly announced that its Phase III study for ramucirumab failed to hit its primary endpoint on progression-free survival among women with metastatic breast cancer. On April 21, 2014, the FDA approved ramucirumab in treating stomach cancer.This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax.".
- Ramucirumab atcPrefix "none".
- Ramucirumab casNumber "947687-13-0".
- Ramucirumab fdaUniiCode "D99YVK4L0X".
- Ramucirumab wikiPageID "19841090".
- Ramucirumab wikiPageRevisionID "606500363".
- Ramucirumab atcPrefix "none".
- Ramucirumab c "6374".
- Ramucirumab casNumber "947687".
- Ramucirumab chemspiderid "NA".
- Ramucirumab h "9864".
- Ramucirumab hasPhotoCollection Ramucirumab.
- Ramucirumab legalStatus "Investigational".
- Ramucirumab mabType "mab".
- Ramucirumab molecularWeight "143.6".
- Ramucirumab n "1692".
- Ramucirumab o "1996".
- Ramucirumab s "46".
- Ramucirumab source "u".
- Ramucirumab target Kinase_insert_domain_receptor.
- Ramucirumab tradename "Cyramza".
- Ramucirumab type "mab".
- Ramucirumab unii "D99YVK4L0X".
- Ramucirumab verifiedfields "changed".
- Ramucirumab verifiedrevid "464380023".
- Ramucirumab subject Category:Monoclonal_antibodies.
- Ramucirumab type Abstraction100002137.
- Ramucirumab type Antibody115027189.
- Ramucirumab type Chemical114806838.
- Ramucirumab type Compound114818238.
- Ramucirumab type Macromolecule114944888.
- Ramucirumab type Material114580897.
- Ramucirumab type Matter100020827.
- Ramucirumab type Molecule114682133.
- Ramucirumab type MonoclonalAntibodies.
- Ramucirumab type MonoclonalAntibody115029781.
- Ramucirumab type OrganicCompound114727670.
- Ramucirumab type Part113809207.
- Ramucirumab type PhysicalEntity100001930.
- Ramucirumab type Protein114728724.
- Ramucirumab type Relation100031921.
- Ramucirumab type Substance100019613.
- Ramucirumab type Thing100002452.
- Ramucirumab type Unit109465459.
- Ramucirumab type Drug.
- Ramucirumab type DrugProduct.
- Ramucirumab type FunctionalSubstance.
- Ramucirumab comment "Ramucirumab (IMC-1121B, trade name Cyramza) is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. It is directed against the vascular endothelial growth factor receptor 2 (VEGFR2). By binding to VEGFR2 it works as a receptor antagonist blocking the binding of vascular endothelial growth factor (VEGF) to VEGFR2.".
- Ramucirumab label "Ramucirumab".
- Ramucirumab label "Ramucirumab".
- Ramucirumab sameAs Ramucirumab.
- Ramucirumab sameAs m.04q28k_.
- Ramucirumab sameAs Q7290345.
- Ramucirumab sameAs Q7290345.
- Ramucirumab sameAs Ramucirumab.
- Ramucirumab wasDerivedFrom Ramucirumab?oldid=606500363.
- Ramucirumab isPrimaryTopicOf Ramucirumab.